#United States #Teaneck #AI Development #Cognizant #Gilead

Cognizant Strengthens Collaboration with Gilead Sciences

Cognizant, a leading technology services provider, recently announced an exciting five-year extension of its partnership with Gilead Sciences. This collaboration aims to further enhance Gilead's digital transformation strategies and innovate their operations through advanced AI-enabled DevOps capabilities.

An Unwavering Commitment to Health

Gilead Sciences has made significant strides in the biopharmaceutical sector, contributing over three decades of groundbreaking work in medicine. Their focus on delivering advanced healthcare solutions aligns perfectly with Cognizant's commitment to bringing technological advancements in the life sciences sector.

Under the renewed agreement, Cognizant will leverage its extensive experience to provide support in Gilead’s technology programs. This includes upgrading Gilead's existing DevOps capabilities and integrating responsible artificial intelligence (AI) applications across critical projects. The goal is to simplify processes and enhance delivery, ultimately allowing Gilead’s teams to execute priority technology programs with greater efficiency.

Enhancing DevOps and AI Integration

For over a decade, Cognizant has been instrumental in facilitating segments of Gilead's global IT framework, encompassing platforms, applications, and advanced analytics. The expanded agreement concentrates on offering deeper support for DevOps and AI-enabled capabilities, which are essential as Gilead fortifies its technological foundations to better serve its business and scientific pursuits.

Anna Berg Asberg, Gilead's Global Chief Information Officer, expressed enthusiasm about the renewed partnership: “Our focus is on giving our teams reliable, efficient technology that helps them move important work forward. This agreement provides additional support as we strengthen our DevOps capabilities and evaluate practical, responsible uses of AI across our technology environment—all in service of our broader mission to deliver for patients.”

Cognizant’s Role in the Partnership

Surya Gummadi, President of Cognizant's Americas division, emphasized the significance of this partnership: “We value the opportunity to continue supporting Gilead's technology priorities. Our work will bring together life sciences experience, DevOps capabilities, and AI tools to help Gilead improve delivery across selected programs.” This reflects Cognizant's commitment to combining its life sciences expertise with cutting-edge technology to meet the demands of the biopharmaceutical sector effectively.

As the partnership unfolds, a focused approach on practical tools and strategies will be essential for promoting operational efficiency and program execution within Gilead. Cognizant's capacity to deliver tailored solutions empowers Gilead to maintain its leadership in scientific innovation, ultimately benefiting patients who rely on their therapies.

About Cognizant

Cognizant stands out as an AI builder and technology service provider, engineering comprehensive AI solutions that bridge the gap between AI investment and business value. With deep industry knowledge and technical expertise, Cognizant crafts unique technological frameworks tailored to amplify human potential and drive substantial returns, keeping global enterprises ahead in a rapidly evolving landscape.

For further information, you can visit Cognizant’s official website at www.cognizant.ai.